Replication licensing factor (RLF) is an essential initiation factor that can prevent re-replication of DNA in a single cell cycle [1, 2] . It is required for the initiation of DNA replication, binds to chromatin early in the cell cycle, is removed from chromatin as DNA replicates and is unable to re-bind replicated chromatin until the following mitosis. 
In order to explore different activities required for licensing, we immunodepleted Xenopus egg extracts with antibodies specific for XOrc1 (to remove XORC), XCdc6 or XMcm3 (to remove RLF-M); non-immune serum was used as a negative control. Extracts were also treated with the kinase inhibitor 6-dimethylaminopurine (6-DMAP), as described [12] , to generate a '6-DMAP extract' that is functionally devoid of RLF activity. Xenopus sperm nuclei were incubated briefly in these extracts to allow proteins to load onto the DNA, and the chromatin was then isolated and immunoblotted with antibodies against XOrc1 and XCdc6 ( Figure 1a ). Consistent with previous reports [9] [10] [11] , both XOrc1 and XCdc6 were assembled onto chromatin in the non-immune control extract (NI -) and extracts without a functional RLF (XMcm3-depleted or 6-DMAP-treated extracts), but XCdc6 was not loaded onto chromatin lacking XORC. In parallel, we measured the ability of the different extracts to license sperm nuclei ( Figure 1b , white bars). Although efficient licensing occurred in extracts mockdepleted with non-immune antibodies, licensing did not occur in buffer or in extracts immunodepleted of either XOrc1, XCdc6 or XMcm3. This demonstrates that, consistent with previous reports [3, 4, [9] [10] [11] , XORC, XCdc6 and XMcm3 are all independently required for licensing naive sperm nuclei. We next determined whether the XORC and XCdc6 assembled onto chromatin in the XMcm3-depleted extract (XMcm3 -chromatin) or in the 6-DMAP-treated extract (6-DMAP chromatin) were functional. Chromatin templates were assembled in the XMcm3-depleted or 6-DMAP-treated extract and were then isolated and incubated for a second time in either buffer or in another immunodepleted extract, before being subjected to a functional licensing assay (Figure 1b) . Both XMcm3 -chromatin and 6-DMAP chromatin were efficiently licensed on subsequent incubation in XOrc1-depleted or XCdc6-depleted extract, but not on incubation in buffer or in the XMcm3-depleted extract (Figure 1b) . This demonstrates that, despite being unlicensed, chromatin assembled in either the XMcm3-depleted extract or in the 6-DMAP extract contains active XORC and XCdc6.
We have previously shown that RLF-M and RLF-B can be separated by differential precipitation with polyethylene glycol (PEG) [3, 13] . We therefore prepared unlicensed chromatin by isolating Xenopus sperm chromatin after incubation in either XMcm3-depleted extract or in 6-DMAP-treated extract. We next determined which RLF components are required for the licensing of this XMcm3 -chromatin and 6-DMAP chromatin. Figure 2 shows that only when these chromatin templates were incubated with both RLF-B and RLF-M fractions did they become functionally licensed. Given that both XMcm3 -chromatin and 6-DMAP chromatin contain functional XORC and XCdc6 and could be licensed in XOrc1-depleted or XCdc6-depleted extract (Figure 1 ), this demonstrates that RLF-B is an essential component of the licensing system that is functionally distinct from both XORC and XCdc6. The requirement for RLF-B in the licensing of chromatin assembled in XMcm3-depleted extract also demonstrates that RLF-B is not simply required to reverse an abnormal effect that occurs in the 6-DMAP-treated extract, but is likely to represent a physiological activity required for the licensing of chromatin in a normal cell cycle.
We then investigated whether the different RLF-B and XCdc6 activities are physically distinct and whether they can be separated from one another. The fractionation of RLF-B over three sequential chromatographic steps (PEG precipitation, phosphocellulose chromatography and ammonium-sulphate precipitation) has been described previously [9, 13] . The resultant fraction (called 'BPAS') contains both XORC and XCdc6 in addition to RLF-B ( [9] and see later). The BPAS fraction was immunodepleted using either antibodies to XCdc6 or non-immune antibodies and the resultant material was then assayed for XCdc6 activity 212 Current Biology, Vol 9 No 4
Figure 1
Unlicensed chromatin contains active XORC and XCdc6. (a) Xenopus sperm nuclei were left untreated (sperm), or were incubated for 15 min in Xenopus interphase extracts previously immunodepleted with antibodies against XOrc1 (XOrc1 -), XCdc6 (XCdc6 -) or XMcm3 (XMcm3 -), or with non-immune antibodies (NI -), or were incubated in 6-DMAP-treated extract. Chromatin was isolated and subjected to SDS-PAGE and immunoblotted with antibodies against XOrc1 and XCdc6. (b) A schematic representation of the experimental procedure is shown on top. Untreated sperm chromatin (sperm) or sperm chromatin previously assembled in either 6-DMAP-treated extract (6-DMAP chromatin) or in XMcm3-depleted extract (XMcm3 -chromatin) was isolated and incubated in buffer or in a second aliquot of extract previously immunodepleted with antibodies against XOrc1, XCdc6 or XMcm3, or with non-immune antibodies, before being transferred to 6-DMAP-treated extract and incubated for a further 90 min with [α-32 P]dATP to assess the degree of licensing. ( Figure 3a ) and RLF-B activity ( Figure 3b ). As shown in Figure 3 , the BPAS fraction had both XCdc6 and RLF-B activity. The XCdc6 activity was completely removed by depletion with anti-XCdc6 antibodies (Figure 3a ). In contrast, the RLF-B activity of the BPAS fraction was not reduced by the depletion of XCdc6 (Figure 3b) , showing that RLF-B had been separated from XCdc6.
As an alternative method of separating RLF-B and XCdc6, we chromatographed the BPAS fraction on phenyl Sepharose. A peak of RLF-B activity eluted at around 500 mM KCl (Figure 4a , fractions 21-25) representing more than 90% of the activity loaded onto the column. In contrast, XOrc1 and XCdc6 were not eluted until much lower salt concentrations, with the majority of XOrc1 and XCdc6 remaining bound to the column under these low salt conditions ( Figure 4b and data not shown). No XCdc6 could be detected in the fractions containing RLF-B activity (note that a very long exposure of the immunoblot is shown in Figure 4b and that 25 times less material was loaded in the BPAS lane (L) than in the individual fractions). Although the BPAS fraction loaded onto the phenyl Sepharose column could restore activity to a XCdc6-depleted extract (Figure 4c) , there was insufficient XCdc6 in either the RLF-B peak (fraction 23) or even in the last fraction of the elution (fraction 31) to provide any XCdc6 activity (Figure 4c ). This demonstrates a clear physical separation of RLF-B and XCdc6 by standard chromatography.
Brief Communication 213 In addition to the experiments shown here demonstrating a clear functional and physical separation of RLF-B from XCdc6, we have also observed that recombinant XCdc6 protein can restore licensing activity to XCdc6-depleted extract, but provides no RLF-B activity (see Supplementary material published with this article on the internet). We are currently attempting to complete the purification of RLF-B in order to identify it and understand its function. Despite it being unidentified, the results shown here strongly suggest that RLF-B acts in concert with RLF-M on chromatin that already contains XORC and XCdc6. Figure 2 shows that both RLF-M and RLF-B are required for the licensing of chromatin previously assembled in an XMcm3-depleted extract. Because XMcm3-depleted extract contains active RLF-B [3] , this demonstrates that RLF-B cannot execute its essential function before RLF-M loading. Given that XCdc6 must be loaded onto chromatin prior to RLF-M ( [10] ; Figure 1 ), these experiments also show that the essential function of RLF-B in licensing can only be executed after XCdc6 has bound to chromatin.
Materials and methods

Preparation of egg extracts
Metaphase-arrested Xenopus egg extracts were prepared as described [13] . For replication assays, they were supplemented with 100 µg/ml cycloheximide, 25 mM phosphocreatine, 15 µg/ml creatine phosphokinase and [α-32 P]dATP, and were then released into interphase with 0.3 mM CaCl 2 . The RLF-defective 6-DMAP extract was prepared in a similar way, except that 3 mM 6-DMAP was added prior to CaCl 2 -stimulated release [12, 13] . Immunodepletion of interphase extracts or the BPAS fraction with antibodies raised against XOrc1 [9] , XCdc6 [10] or XMcm3 [5] , or with antibodies from non-immune rabbit serum, was performed as described [13] . Control extracts were diluted with an equivalent amount of buffer. As soon as immunodepletion was complete, extracts were snap frozen in liquid nitrogen in 10 µl aliquots for future use.
Chromatin templates
Demembranated Xenopus sperm nuclei were prepared as described [13] . They were assembled into chromatin by incubation for 15 min at 23°C in 6-DMAP extracts at 20,000-40,000 nuclei per µl (50-100 ng DNA per µl) or in immunodepleted extracts at 10,000-13,000 nuclei per µl (25-30 ng DNA per µl). The extract was then diluted 10-fold in nuclear isolation buffer [13] (NIB: 50 mM KCl, 50 mM Hepes-KOH pH 7.6, 5 mM MgCl 2 , 2 mM DTT, 0.5 mM spermine 3HCl, 0.15 mM spermine 4HCl, 1 µg/ml of each of aprotinin, leupeptin and pepstatin) supplemented with 2.5 mM Mg-ATP and 0.01% Triton-X-100, and then underlayered with the same buffer containing 15% sucrose. Chromatin was then pelleted at 1,500 × g in a swinging bucket centrifuge for 5 min at 4°C, and was resuspended in NIB supplemented with 2.5 mM Mg-ATP and 0.01% Triton-X-100. Aliquots of pelleted chromatin were either used for replication assays or immunoblotted by standard techniques using 10% SDS-PAGE and ECL visualisation (Amersham).
Chromatography
The BPAS fraction was prepared as described [9, 13] . For phenyl Sepharose chromatography, BPAS was made 1 M with respect to KCl in Hepes buffer (20 mM Hepes-KOH pH 8, 10% sucrose, 1 µg/ml of each of aprotinin, leupeptin and pepstatin) and applied to a 1 ml HiTrap phenyl Sepharose column (Pharmacia) equilibrated in the same buffer.
The column was developed with a gradient over three column volumes to Hepes buffer without KCl. In order to overcome the inhibitory effect of the high salt on the RLF-B and XCdc6 assays, aliquots were diluted five-fold with Hepes buffer prior to assay. For blotting, aliquots were precipitated using DOC-TCA as follows: 50% of each sample was supplemented with 0.015% deoxycholate, mixed and incubated for 10 min at room temperature, supplemented with 5% trichloroacetic acid, mixed and microfuged for 5 min. The supernatant was removed and the pellet was resuspended in 0.01 N NaOH.
Replication assays
DNA synthesis was measured by the incorporation of [α-32 P]dATP into acid-insoluble material as described [13] . Licensing assays were performed by measuring DNA synthesis in 6-DMAP-treated extract as described [3, 13] . Briefly, 0.3 µl chromatin templates were incubated with 2 µl assay fractions for 15 min. The reaction was then supplemented with 5.7 µl 6-DMAP extract containing [α-32 P]dATP and the incubation continued for a further 90 min, after which time the total amount of DNA synthesis was measured. All incubations were performed at 23°C.
Supplementary material
A figure showing that recombinant XCdc6 does not have RLF-B activity is published with this paper on the internet. 
